GEN-MKT-18-7897-A
Feb 12, 2025 | Blogs, Discovery, Echo® MS+ system, Pharma, QA/QC | 0 comments
Read time: 2 minutes
On average, it takes 10-15 years and 1-2 billion dollars to approve a new pharmaceutical for clinical use. Since approximately 90% of new drug candidates fail in clinical development, the ability to make early, informed and accurate decisions on the safety and efficacy of new hits and leads is key to increasing the chances of success.
To achieve this drug discovery assays require speed and accuracy, but often scientists must compromise on one of these requirements to cope with the thousands of samples that need to be analyzed.
The Echo® MS+ system allows pharmaceutical companies to make data-driven decisions early in the drug discovery process, saving time and money, and potentially getting their drug to market faster than with more traditional approaches. Common analytical techniques such as LC-MS or fluorescence are limited by either sample throughput or accuracy of results.
Learn more >
The Echo® MS+ system uses acoustic ejection mass spectrometry (AEMS) technology. Samples are placed into a compatible well plate which is held in the Echo® MS+ system’s autosampler. Here sound energy is applied to the bottom of each well individually. The sound energy causes reproducible droplets to be ejected from the well for capture in a carrier solvent of the OPI for dilution and transfer to the mass spectrometer’s source. From this point, the diluted sample is ionized using conventional electrospray ionization, ready for detection.
Watch video >
The Echo® MS+ system is a novel platform for Acoustic Ejection Mass Spectrometry (AEMS) and combines the speed of acoustic sampling with the selectivity of mass spectrometry. This platform has been designed for high throughput analysis of small and large molecules. The technology combines Acoustic Droplet Ejection (ADE), an Open Port Interface (OPI) and could be coupled with the SCIEX Triple Quad 6500+ system or the ZenoTOF 7600 system.
The Echo® MS+ system comprises of an open-port interface (OPI) and acoustic droplet ejection (ADE) module which could be coupled with a mass spectrometer. The mass spectrometer could either be a SCIEX Triple Quad 6500+ system or the ZenoTOF 7600 system. This non-liquid chromatography based; high-throughput screening platform enables rapid analysis of compounds at speeds of up to 1 sample/second.
The ability to consistently achieve reproducible results on many complex samples across multiple days is critical to a routine clinical laboratory. Laboratories relying on analytical instrumentation require stability and robustness to perform a variety of screening and confirmatory assays with confidence. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) has become the preferred analytical method in the clinical laboratory to reliably perform clinical testing as it provides best-in-class performance and reliability for the most challenging assays. LC-MS/MS offers the required levels of sensitivity and specificity for the detection and quantitation of molecules from complex biological samples, helping laboratories deliver highly accurate data for a variety of clinically relevant analytes across a wide range of assays.
Posted by
You must be logged in to post a comment.
Share this post with your network